Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217267 | 1.00 | CAPN2 (0.52) | CAPN2CPB2 | |
| SCHEMBL2217115 | 0.89 | CPB2 (0.54) | CAPN2CPB2 | |
| SCHEMBL2217113 | 0.89 | CPB2 (0.54) | CAPN2CPB2 | |
| SCHEMBL15372879 | 0.85 | CPB2 (0.62) | CAPN2CPB2 | |
| SCHEMBL2217255 | 0.85 | CPB2 (0.58) | CAPN2CPB2 | |
| SCHEMBL15372880 | 0.85 | CPB2 (0.62) | CAPN2CPB2 | |
| SCHEMBL2217259 | 0.82 | CPB2 (0.56) | CAPN2CPB2 | |
| SCHEMBL2217106 | 0.79 | CPB2 (0.68) | CAPN2CPB2 | |
| SCHEMBL13577798 | 0.79 | CPB2 (0.49) | CAPN2CPB2 | |
| SCHEMBL15372869 | 0.79 | CPB2 (0.74) | CAPN2CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309207-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2016-04-12 | — | — | US | disclosed |
| US-9126955-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI (FR) | 2014-07-24 | — | — | US | disclosed |
| US-8722655-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | CAPN2 542/4885CPB2 41/4885 |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | CAPN2 579/4885CPB2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.